Breast Cancer (ESR1 and PIK3CA cfDNA Testing) [Plasma]

Molecular Pathology

02-BRCA-ESR1-27

ESR1 and PIK3CA testing in cfDNA (plasma) for metastatic breast cancer. This EQA is sponsored.

Sponsored by

Overview

The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.

At a glance

Product Code:

02-BRCA-ESR1-27

Target/Genes:

The scope of this EQA includes testing for actionable and resistant variants in the ESR1 and PIK3CA genes in cfDNA plasma in metastatic breast cancer in the context of targeted therapies, such as SERDs and PI3K inhibitors.

Technology:

NGS, Panel testing, PCR based

Sample Type:

Plasma (cfDNA)

Submit Results In:

English, French, German, Italian, Spanish

Accredited:

Pending

Key Dates

Register by

28/02/2027

Samples ship

Sep-27

Survey Period

September - November 2027

Final Results

May - June 2028

Sample Details

Three mock clinical cases; 2 with matching samples and 1 virtual case will be provided will be provided, 3ml artificial / synthetic plasma is provided per case. Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test the samples according to their routine strategy, to return a clinical report and to complete the data collection form.

This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. EMQN acknowledge and thank AstraZeneca for this support.

Restricted to 120 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).

Send your enquiry by submitting the form

Closes in 111 days

From £310.00

Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.

Add to enquiry list
  • Submit results in 5 languages

Questions about this scheme?
Contact our team

Register Interest

Express your interest in ''.

Watch on YouTube (opens in a new tab)